Boysen Bio ApS: Financial statements 2023
CVR: 38655590
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
Boysen Bio ApS (CVR 38655590) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -5,105 and a net result of DKK -5,110 compared with DKK -5,062 the year before. Equity in the 2023 report amounted to DKK 51,166. The solvency ratio was 19.9%.
- Gross Profit
- DKK -5,105
- Profit/Loss
- DKK -5,110
- Equity
- DKK 51,166
- Total Assets
- DKK 256,941
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -5 t. | -5 t. | 51 t. | - |
| 2022 | - | -5 t. | -5 t. | 56 t. | - |
| 2021 | - | -4 t. | -4 t. | 21 t. | - |
| 2020 | - | -4 t. | -4 t. | 25 t. | - |
| 2019 | - | -9 t. | -18 t. | 29 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout Boysen Bio ApS
Boysen Bio ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2017. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named Boysen Bio IVS and GlyProVac IVS. The management consists of Anders Boysen. The company is owned by Anders Boysen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,142 and a net result of DKK -4,142 compared with DKK -4,968 the year before. Equity in the 2025 report amounted to DKK 42,055.